第八年度 INTERMACS 报告：特别关注不良事件影响的构建。
Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.
机构信息
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan.
出版信息
J Heart Lung Transplant. 2017 Oct;36(10):1080-1086. doi: 10.1016/j.healun.2017.07.005. Epub 2017 Jul 15.
BACKGROUND
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database now includes >20,000 patients from >180 hospitals.
METHODS
The eighth annual report of INTERMACS updates the first decade of patient enrollment.
RESULTS
In the current era, >95% of implants are continuous flow devices. Overall survival continues to remain >80% at 1 year and 70% at 2 years. Review of major adverse events shows minimal advantage for patients with ambulatory heart failure pre-implant. Stroke, major infection, and continued inotrope requirement during the first 3 months have a major effect on subsequent survival.
CONCLUSIONS
Greater application of durable devices to patients with ambulatory heart failure will mandate more effective neutralization or prevention of major adverse events.
背景
机械循环辅助装置注册机构（INTERMACS）数据库现在包含来自 180 多家医院的 20,000 多名患者。
方法
INTERMACS 的第八次年度报告更新了前十年的患者入组情况。
结果
在当前时代，超过 95%的植入物为连续流设备。1 年和 2 年的总体生存率分别持续保持在 80%以上和 70%以上。对重大不良事件的审查表明，植入前有活动能力的心力衰竭患者的优势微乎其微。卒中、严重感染和前 3 个月持续使用儿茶酚胺类药物对随后的生存有重大影响。
结论
将耐用设备更广泛地应用于有活动能力的心力衰竭患者将需要更有效地中和或预防重大不良事件。
Zotero 插件